{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:14:31Z","timestamp":1789917271062,"version":"4.0.1"},"reference-count":122,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bprclinrheum.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.berh.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T09:46:14Z","timestamp":1462959974000},"page":"112-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Raynaud's phenomenon"],"prefix":"10.1016","volume":"30","author":[{"given":"Michael","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane L.","family":"Herrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.berh.2016.04.001_bib1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/rheumatology\/keq310","article-title":"Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey","volume":"50","author":"Bassel","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.berh.2016.04.001_bib2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/rheumatology\/kev002","article-title":"Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"6752","key":"10.1016\/j.berh.2016.04.001_bib3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/bmj.301.6752.590","article-title":"Prevalence of symptoms of Raynaud's phenomenon in general practice","volume":"301","author":"Silman","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/j.berh.2016.04.001_bib4","series-title":"Raynaud's phenomenon: a guide to pathogenesis and treatment","first-page":"21","article-title":"Epidemiology of Raynaud's phenomenon","author":"Maundrell","year":"2015"},{"issue":"8","key":"10.1016\/j.berh.2016.04.001_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","article-title":"The pathogenesis, diagnosis and treatment of Raynaud phenomenon","volume":"8","author":"Herrick","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib6","first-page":"485","article-title":"Raynaud's phenomenon: a proposal for classification","volume":"10","author":"LeRoy","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2016.04.001_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.01.020","article-title":"International consensus criteria for the diagnosis of Raynaud's phenomenon","volume":"48\u201349","author":"Maverakis","year":"2014","journal-title":"J\u00a0Autoimmun"},{"issue":"13","key":"10.1016\/j.berh.2016.04.001_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","article-title":"Raynaud's phenomenon","volume":"347","author":"Wigley","year":"2002","journal-title":"N\u00a0Eng J Med"},{"issue":"12","key":"10.1016\/j.berh.2016.04.001_bib9","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/art.1780160506","article-title":"Patterns of finger capillary abnormalities in connective tissue disease by 'wide-field' microscopy","volume":"16","author":"Maricq","year":"1973","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2016.04.001_bib11","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/art.27543","article-title":"Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis","volume":"62","author":"Herrick","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2016.04.001_bib12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2010.104","article-title":"Assessing microvascular changes in systemic sclerosis diagnosis and management","volume":"6","author":"Cutolo","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2016.04.001_bib13","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/rheumatology\/keq051","article-title":"Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathies","volume":"49","author":"Mercer","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.semarthrit.2008.09.003","article-title":"Nailfold microscopy in adults with inflammatory myopathy","volume":"39","author":"Selva-O'Callaghan","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib15","first-page":"754","article-title":"Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis","volume":"25","author":"Hudson","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2016.04.001_bib16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s10067-006-0489-6","article-title":"Office capillaroscopy in systemic sclerosis","volume":"26","author":"Baron","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2016.04.001_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard.60.4.407","article-title":"Differentiation between primary and secondary Raynaud's phenomenon: a prospective study comparing nailfold capillaroscopy using an opthalmoscope or stereomicroscope","volume":"60","author":"Anders","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2016.04.001_bib18","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/rheumatology\/keu533","article-title":"A\u00a0study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis-spectrum disorders","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/art.24394","article-title":"Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients","volume":"61","author":"Sebastiani","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2016.04.001_bib20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/ard.2010.132431","article-title":"Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions","volume":"70","author":"Smith","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2016.04.001_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/CH-141809","article-title":"Prediction risk chart for scleroderma digital ulcers: a composite predictive model based on capillaroscopic, demographic and clinico-serological parameters","volume":"59","author":"Manfredi","year":"2015","journal-title":"Clin Hemorheol Microcirc"},{"issue":"10","key":"10.1016\/j.berh.2016.04.001_bib22","first-page":"S848","article-title":"A\u00a0multicenter, prospective cohort study using nailfold videocapillaroscopy and other clinical characteristics to determine the risk of developing new digital ulcers in patients with systemic sclerosis","volume":"66","author":"Smith","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/rheumatology\/kel330","article-title":"The \u2018distal-dorsal difference\u2019: a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon","volume":"46","author":"Anderson","year":"2007","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2016.04.001_bib24","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/ard.51.11.1193","article-title":"Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis","volume":"51","author":"O'Reilly","year":"1992","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.mvr.2011.03.007","article-title":"Influence of the cold challenge on the discriminatory capacity of the digital distal-dorsal difference in the thermographic assessment of Raynaud's phenomenon","volume":"82","author":"Pauling","year":"2011","journal-title":"Microvasc Res"},{"key":"10.1016\/j.berh.2016.04.001_bib26","first-page":"127","article-title":"Vascular diagnostics for Raynaud's phenomenon","volume":"2","author":"Dinsdale","year":"2014","journal-title":"J\u00a0Vasc Diagn"},{"key":"10.1016\/j.berh.2016.04.001_bib27","series-title":"Raynaud's phenomenon: a guide to pathogenesis and treatment","first-page":"199","article-title":"Non-invasive methods of assessing Raynaud's phenomenon","author":"Murray","year":"2015"},{"issue":"7","key":"10.1016\/j.berh.2016.04.001_bib28","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1088\/0967-3334\/35\/7\/R91","article-title":"Microvascular imaging: techniques and opportunities for clinical physiological measurements","volume":"35","author":"Allen","year":"2014","journal-title":"Physiol Meas"},{"issue":"10","key":"10.1016\/j.berh.2016.04.001_bib29","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/rheumatology\/keh275","article-title":"Laser Doppler imaging: a developing technique for application in the rheumatic diseases","volume":"43","author":"Murray","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.berh.2016.04.001_bib30","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3899\/jrheum.141437","article-title":"Use of laser speckle contrast imaging to assess digital microvascular function in primary Raynaud phenomeon and systemic sclerosis: a comparison using the Raynaud Condition Score Diary","volume":"42","author":"Pauling","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2016.04.001_bib31","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2016.04.001_bib32","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2016.04.001_bib33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2016.04.001_bib34","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2016.04.001_bib36","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","article-title":"Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis","volume":"73","author":"Minier","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L","article-title":"Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings","volume":"42","author":"Burdt","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2016.04.001_bib38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0002-9343(72)90064-2","article-title":"Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)","volume":"52","author":"Sharp","year":"1972","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2016.04.001_bib39","series-title":"Raynaud's phenomenon: a guide to pathogenesis and treatment","first-page":"116","article-title":"Secondary Raynaud's phenomenon","author":"Ong","year":"2015"},{"issue":"2","key":"10.1016\/j.berh.2016.04.001_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/art.1780230208","article-title":"Diagnostic potential of in\u00a0vivo capillary microscopy in scleroderma and related disorders","volume":"23","author":"Maricq","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2016.04.001_bib41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0961203307076517","article-title":"Capillaroscopy is a dynamic process in mixed connective tissue disease","volume":"16","author":"de Holanda Mafaldo Di\u00f3genes","year":"2007","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.berh.2016.04.001_bib42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1191\/096120398678919787","article-title":"Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year","volume":"7","author":"Mosca","year":"1998","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.berh.2016.04.001_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10067-004-0988-2","article-title":"Raynaud's phenomenon in undifferentiated connective tissue disease (UCTD)","volume":"24","author":"De Angelis","year":"2005","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/29.3.205","article-title":"Raynaud's phenomenon in primary Sj\u00f6gren's syndrome","volume":"29","author":"Youinou","year":"1990","journal-title":"Br J Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib45","first-page":"618","article-title":"Raynaud's phenomenon in primary Sj\u00f6gren's syndrome","volume":"17","author":"Skopouli","year":"1990","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2016.04.001_bib46","first-page":"1572","article-title":"Raynaud's phenomenon in primary Sj\u00f6gren's syndrome. Association with other extraglandular manifestations","volume":"19","author":"Kraus","year":"1992","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/ard.42.5.533","article-title":"HLA DR alloantigens in different subsets of patients with Sj\u00f6gren's syndrome and in family members","volume":"42","author":"Mann","year":"1983","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib48","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/rheumatology\/29.6.493","article-title":"Raynaud's phenomenon and primary Sj\u00f6gren's syndrome","volume":"29","author":"Foster","year":"1990","journal-title":"Br J Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2016.04.001_bib49","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/ar2958","article-title":"Anticentromere antibody positive Sj\u00f6gren's Syndrome: a retrospective descriptive analysis","volume":"12","author":"Bournia","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2016.04.001_bib50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2474-11-140","article-title":"Anti-centromere antibody-seropositive Sj\u00f6gren's syndrome differs from conventional subgroup in clinical and pathological study","volume":"11","author":"Nakamura","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"issue":"9","key":"10.1016\/j.berh.2016.04.001_bib51","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/ard.2003.013417","article-title":"Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus","volume":"63","author":"Hoffman","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2016.04.001_bib52","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00296-012-2449-6","article-title":"Is there a difference in systemic lupus erythematosus with and without Raynaud's phenomenon?","volume":"33","author":"Pavlov-Dolijanovic","year":"2013","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.berh.2016.04.001_bib53","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1177\/0961203311403640","article-title":"Clinical expression and morbidity of systemic lupus erythematosus during a post-diagnostic 5-year follow-up: a male:female comparison","volume":"20","author":"Stefanidou","year":"2011","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.berh.2016.04.001_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00296-013-2798-9","article-title":"Sex differences in patients with systemic lupus erythematosus from Northwest Spain","volume":"34","author":"Alonso","year":"2014","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib55","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/01.md.0000147737.57861.7c","article-title":"Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature","volume":"83","author":"Boddaert","year":"2004","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/11598550-000000000-00000","article-title":"Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment","volume":"29","author":"Arnaud","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.berh.2016.04.001_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4137\/CMAMD.S7667","article-title":"Asymptomatic pulmonary hypertension in systemic lupus erythematosus","volume":"4","author":"Kamel","year":"2011","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"issue":"4","key":"10.1016\/j.berh.2016.04.001_bib58","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0190-9622(98)70116-1","article-title":"Abnormal IgG cardiolipin antibody titers in patients with Raynaud's phenomenon and\/or related disorders: prevalence and clinical significance","volume":"38","author":"Vayssairat","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.berh.2016.04.001_bib59","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.62.10.1003","article-title":"Raynaud's phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association?","volume":"62","author":"Caccavo","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib60","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1590\/abd1806-4841.20153881","article-title":"Systemic lupus erythematosus and Raynaud's phenomenon","volume":"90","author":"Heimovski","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2016.04.001_bib61","first-page":"307","article-title":"Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and Raynaud's phenomenon","volume":"25","author":"Rodriguez","year":"2006","journal-title":"P\u00a0R Health Sci J"},{"issue":"1","key":"10.1016\/j.berh.2016.04.001_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1191\/0961203302lu144oa","article-title":"Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients","volume":"11","author":"Furtado","year":"2002","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.berh.2016.04.001_bib63","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","article-title":"Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort","volume":"74","author":"Dobloug","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib64","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11926-011-0176-8","article-title":"Antisynthetase syndrome","volume":"13","author":"Katzap","year":"2011","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib65","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/08916930600623767","article-title":"Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies","volume":"39","author":"Mielnik","year":"2006","journal-title":"Autoimmunity"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib66","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22498","article-title":"Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease","volume":"67","author":"Narang","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib67","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archinte.158.6.595","article-title":"Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases","volume":"158","author":"Spencer-Green","year":"1998","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib68","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/art.21912","article-title":"Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance","volume":"54","author":"Hirschl","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2016.04.001_bib69","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1007\/s00296-011-2109-2","article-title":"Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon","volume":"32","author":"Pavlov-Dolijanovic","year":"2012","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.berh.2016.04.001_bib70","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4081\/reumatismo.2013.186","article-title":"Prospective capillaroscopy-based study on transition from primary to secondary Raynaud's phenomenon: preliminary results","volume":"65","author":"Bernero","year":"2013","journal-title":"Reumatismo"},{"issue":"4","key":"10.1016\/j.berh.2016.04.001_bib71","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/rheumatology\/kep447","article-title":"Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy","volume":"49","author":"Ingegnoli","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib72","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1525-1470.2006.00278.x","article-title":"The prognostic value of nailfold capillary changes for the development of connective tissue disease in children and adolescents with primary Raynaud phenomenon: a follow-up study of 250 patients","volume":"23","author":"Pavlov-Dolijanovi\u0107","year":"2006","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib73","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/art.22636","article-title":"Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et\u00a0al.","volume":"56","author":"Cutolo","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2016.04.001_bib74","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/rheumatology\/kev201","article-title":"Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.berh.2016.04.001_bib75","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/art.10685","article-title":"Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis","volume":"46","author":"Harrison","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2016.04.001_bib76","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/art.30071","article-title":"Canadian Scleroderma Research Group. Cigarette smoking in patients with systemic sclerosis","volume":"63","author":"Hudson","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib77","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2016.04.001_bib78","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","article-title":"Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis","volume":"44","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.04.001_bib79","series-title":"Novel insights into systemic sclerosis management","first-page":"2","article-title":"Prophylactic ACE inhibitor therapy in Raynaud's phenomenon: helpful or harmful?","author":"Hughes","year":"2013"},{"issue":"11","key":"10.1016\/j.berh.2016.04.001_bib80","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","article-title":"Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril","volume":"56","author":"Gliddon","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2016.04.001_bib81","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2016.04.001_bib82","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1874192401004010302","article-title":"The Endothelium and its role in regulating vascular tone","volume":"4","author":"Sandoo","year":"2010","journal-title":"Open Cardiovasc Med J"},{"issue":"7","key":"10.1016\/j.berh.2016.04.001_bib83","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","article-title":"Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon","volume":"34","author":"Teh","year":"1995","journal-title":"Br J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib84","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib85","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/41.3.324","article-title":"Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis","volume":"41","author":"Anderson","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.berh.2016.04.001_bib86","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1136\/annrheumdis-2012-201536","article-title":"A\u00a0multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon","volume":"72","author":"Hummers","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2016.04.001_bib87","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2016.04.001_bib88","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/rheumatology\/ket417","article-title":"Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double blind, randomized, cross-over study","volume":"53","author":"Lee","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 10","key":"10.1016\/j.berh.2016.04.001_bib89","first-page":"2086","article-title":"Efficacy of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis: a double-blind randomized placebo-controlled parallel group multicentric study [abstract]","volume":"62","author":"Agarwal","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib90","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","article-title":"Modified- release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"15","key":"10.1016\/j.berh.2016.04.001_bib91","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinternmed.2012.2271","article-title":"Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study","volume":"172","author":"Caglayan","year":"2012","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.berh.2016.04.001_bib92","first-page":"CD000953","article-title":"Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib93","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"issue":"8320","key":"10.1016\/j.berh.2016.04.001_bib94","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(83)91624-0","article-title":"Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial","volume":"1","author":"Belch","year":"1983","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.berh.2016.04.001_bib95","first-page":"CD000956","article-title":"Prazosin for Raynaud's phenomenon in progressive systemic sclerosis","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.berh.2016.04.001_bib96","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2016.04.001_bib97","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1196\/annals.1423.070","article-title":"Statins as immunomodulators in systemic sclerosis","volume":"1110","author":"Abou-Raya","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"10.1016\/j.berh.2016.04.001_bib98","first-page":"1323","article-title":"Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis","volume":"35","author":"Del Papa","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2016.04.001_bib99","article-title":"A\u00a0review of the effects of statins in systemic sclerosis","author":"Ladak","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib100","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/rheumatology\/keq003","article-title":"Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis","volume":"49","author":"Sadik","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.berh.2016.04.001_bib101","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.1780271009","article-title":"Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin","volume":"27","author":"Beckett","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2016.04.001_bib102","first-page":"499","article-title":"Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study","volume":"18","author":"Denton","year":"2000","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2016.04.001_bib103","first-page":"2257","article-title":"Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study","volume":"28","author":"Sambo","year":"2001","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib104","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.rbr.2014.07.001","article-title":"Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial","volume":"54","author":"Correa","year":"2014","journal-title":"Rev Bras Reumatol"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib105","first-page":"349","article-title":"A\u00a0double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis","volume":"18","author":"Herrick","year":"2000","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2016.04.001_bib106","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrrheum.2014.195","article-title":"A\u00a0vascular mechanistic approach to understanding Raynaud phenomenon","volume":"11","author":"Flavahan","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib107","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/acr.21622","article-title":"Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon","volume":"64","author":"Fava","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib108","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/rheumatology\/ket421","article-title":"A\u00a0double-blind, randomized, placebo-controlled crossover trial of the \u03b12C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis","volume":"53","author":"Herrick","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.berh.2016.04.001_bib109","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.59.1.39","article-title":"Macrovascular disease and systemic sclerosis","volume":"59","author":"Ho","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib110","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1365-2133.2006.07475.x","article-title":"Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis","volume":"155","author":"Hasegawa","year":"2006","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.berh.2016.04.001_bib111","first-page":"168","article-title":"Cervicothoracic sympathectomy for Raynaud's syndrome","volume":"12","author":"Lowell","year":"1993","journal-title":"Int Angiol"},{"key":"10.1016\/j.berh.2016.04.001_bib112","article-title":"Raynaud's phenomenon (secondary). Systematic review","author":"Herrick","year":"2014","journal-title":"BMJ Clin Evid"},{"issue":"4","key":"10.1016\/j.berh.2016.04.001_bib113","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.semarthrit.2011.07.006","article-title":"Botulinum toxin A treatment of Raynaud's phenomenon: a review","volume":"41","author":"Iorio","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2016.04.001_bib114","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.jhsa.2010.09.019","article-title":"Botulinum toxin type A in the treatment of Raynaud's phenomenon","volume":"35","author":"Neumeister","year":"2010","journal-title":"J\u00a0Hand Surg Am"},{"issue":"1","key":"10.1016\/j.berh.2016.04.001_bib115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1346-8138.13030","article-title":"Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study","volume":"43","author":"Motegi","year":"2016","journal-title":"J\u00a0Dermatol"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib116","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/jhsu.2002.35887","article-title":"Adventitial stripping of the radial and ulnar arteries in Raynaud's disease","volume":"27","author":"Balogh","year":"2002","journal-title":"J\u00a0Hand Surg Am"},{"issue":"8","key":"10.1016\/j.berh.2016.04.001_bib117","first-page":"1788","article-title":"A\u00a0systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia","volume":"30","author":"Kotsis","year":"2003","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib118","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/micr.22379","article-title":"Surgical treatment of systemic sclerosis-is it justified to offer peripheral sympathectomy earlier in the disease process?","volume":"35","author":"Momeni","year":"2015","journal-title":"Microsurgery"},{"issue":"5","key":"10.1016\/j.berh.2016.04.001_bib119","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/PRS.0000000000000104","article-title":"Fat grafting to the hand in patients with Raynaud phenomenon: a novel therapeutic modality","volume":"133","author":"Bank","year":"2014","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"10.1016\/j.berh.2016.04.001_bib120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.2007.072686","article-title":"Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis","volume":"67","author":"Nihtyanova","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2016.04.001_bib121","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/art.1780350614","article-title":"Anti-centromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis","volume":"35","author":"Wigley","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2016.04.001_bib122","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1002\/art.24684","article-title":"Independent association of anti-\u03b22-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients","volume":"60","author":"Boin","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694216300018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694216300018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T14:05:48Z","timestamp":1600524348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694216300018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1521694216300018"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2016.04.001","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Raynaud's phenomenon","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}